DUBLIN--(BUSINESS WIRE)--The "Diabetes Injection Pens Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
The report on global diabetes injection pens market provides qualitative and quantitative analysis for the period of 2016 to 2024. The report predicts the global diabetes injection pens market to grow with a CAGR of 8.3% over the forecast period of 2018-2024.
Insulin Pen Needles are used in conjunction with an Insulin pen for the injection of insulin. They come in a variety of needle lengths and diameters and are individually wrapped to keep them sterile. Diabetic Insulin pens resemble that of a pen one uses to write. Their working is similar to that of insulin syringes.
They come in both reusable and disposable versions. Reusable models use a cartridge filled with insulin. Disposable pens come pre-filled with insulin. Major advantages of using an insulin pen include memory storage and being easy & convenient to use.
The increasing demand for next generation insulin pens/intelligent pens is driving the diabetes injection pen market; intelligent pens are the most common and preferred for insulin injecting. These pens are simple to use and come in both disposable and reusable versions.
North America accounted for the largest market share in 2017, followed by Europe. Presence of major medical devices companies and presence of specialty clinics for diabetics' management in these two regions have driven the growth in these regions over the past couple of years. Furthermore, increased awareness about diabetes self-management education would also augment market growth.
The Asia-Pacific region is projected to grow at a swifter rate compared to other regions, on the backdrop of propelling per capita healthcare expenditure, growing healthcare infrastructure and rising awareness level about the usage of injection pens in the primary markets of Asia-Pacific such as India, China and South East Asian countries.
- Sanofi S.A
- Becton, Dickinson and Company
- Owen Mumford Ltd
- Novo Nordisk A/S,
- Eli Lilly and Company
- AstraZeneca plc
- Jiangsu Delfu Co.
- Ypsomed Holding AG.
- Insulet Corporation
- Biocon Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/k5f4mc/global_diabetes?w=44